Mutation and methylation status of p53 gene promoter in human breast tumours

Tumor Biology

Volumn 20, Issue 6, 1999, Pages 341-346

  Nayak, B K ^a   Das, B R ^a  

^a INSTITUTE OF LIFE SCIENCES   (India)

Author keywords

Breast tumour; Methylation; Mutation; p53 promoter

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; BREAST CARCINOGENESIS; BREAST TUMOR; DEAMINATION; EXON; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 0032722106     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000030098     Document Type: Article

References (38)

1. Hollstein M, Sidransky D, Vogelstein B, Harris C: p53 mutations in human cancers. Science 1991;253: 49-53.
2. Gottlieb TM, Oren M: p53 in growth control and neoplasia. Biochim Biophys Acta 1996;1287:77-102.
3. Levine AJ: p53, the cellular gate-keeper for growth and division. Cell 1997;88:323-331.
4. Jacks T, Weinberg RA: Cell cycle control and its watchman. Nature 1996;351:643-644.
5. Gire V, Wynford-Thomas D: Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol Cell Biol 1998;8: 1611-1621.
6. Polyak K, Xia Y, Zewier JL, Kinzler KW, Vogelstein B: A model for p53-induced apoptosis. Nature 1997; 389:300-305.
7. Hall PA, Lane DP: Tumour suppressors: A developing role for p53? Curr Biol 1997;7:R144-R147.
8. Ko LJ, Prives C: p53: Puzzle and paradigm. Genes Dev 1996;10: 1054-1072.
9. Schafer H, Trauzold A, Sebens T, Deppert W, Folsch UR, Schmidt WE: The proliferation associated early response gene p22/PRG1 is a novel p53 target gene. Oncogene 1998;16:2479-2487.
10. Ori A, Zauberman A, Doitsh G, Paran N, Oren M, Shaul Y: p53 binds and represses the HBV enhancer: An adjacent enhancer element can reverse the transcription effect of P53. EMBO J 1998;17:544-553.
11. Dugimont T, Montpellier C, Adriaenssens E, Lottin S, Dumont L, Iotsova V, Lagrou C, Stehelin D, Coll J, Curgy J: The H19 TATA-less promoter is efficiently repressed by wild type tumour suppressor p53. Oncogene 1998;16:2395-2401.
12. Nayak BK, Patnaik S, Das BR: Rearrangement of p53 gene in human breast tumours. Biochem Biophys Res Commun 1998;245:388-391.
13. Furlong EM, Rain T, Martin F: YY1 and NF1 both activate the human p53 promoter alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity. Mol Cell Biol 1996;16:5933-5945.
14. Gottlieb E, Haffner R, King A, Asher G, Gruss P, Lonai P, Oren M: Transgenic mouse model for studying the transcriptional activity of p53. EMBO J 1997;16:1381-1390.
15. Nayak BK, Das BR: Differential binding of nuclear proteins to p53 gene promoter in male breast tumour. Eur J Cancer 1997;33:1484-1487.
16. Fu L, Minden MD, Benchimol S: Translational regulation of human p53 gene expression. EMBO J 1996; 15:4392-4401.
17. Jones PA: DNA methylation errors and cancer. Cancer Res 1996;56: 2463-2467.
18. Tornaletti S, Pfeifer GP: Complete and tissue independent methylation of CpG sites in the p53 gene: Implications for mutations in human cancers. Oncogene 1995;10:1493-1499.
19. Bird A: The essentials of DNA methylation. Cell 1992;70:5-8.
20. Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of 5′CpG island of p16/CDKN2 tumour suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995;55:4551-4555.
21. Foster SA, Wong DJ, Barrett MT, Galloway DA: Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol Cell Biol 1998;18:1793-1801.
22. Ohtani-Fujita N, Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T: CpG methylation inactivates the promoter activity of the human retinoblastoma tumour suppressor gene. Oncogene 1993;8:1063-1067.
23. Kleymenova EV, Yuan X, LaBate ME, Walker CL: Identification of a tumour-specific methylation site in the Wilms tumour suppressor gene. Oncogene 1998;16:713-720.
24. Mancini DN, Rodenhiser DI, Ainsworth PJ, Malley FP, Singh SV, Xing W, Archer TK: CpG methylation within the 5′ regulatory region of the BRCA1 gene is tumour specific and includes a putative CREB binding site. Oncogene 1998;16: 1161-1169.
25. Feinberg AP, Vogelstein B: Hypomethylation of ras oncogenes in primary human cancers. Biochem Biophys Res Commun 1983;111:47-54.
26. Cheah MSC, Wallace CD, Hoffman RM: Hypomethylation of DNA in human cancer cells: A site-specific change in the c-myc oncogene. J Natl Cancer Inst 1984;73:1057-1065.
27. Magewu AN, Jones PA: Ubiquitous and tenacious methylation of CpG site in codon 248 of the p53 gene may explain its frequent appearance as a mutation hotspot in human cancer. Mol Cell Biol 1994;14:4225-4232.
28. Schroeder M, Mass MJ: CpG methylation inactivates the transcriptional activity of the p53 promoter of the human p53 tumour suppressor gene. Biochem Biphys Res Commun 1997;235:403-406.
29. Blin N, Stafford DW: A general method for isolation of high molecular weight DNA from cukaryotes. Nucleic Acids Res 1976;3:2303.
30. Hayashi K: PCR-SSCP: A simple and sensitive method for detection of mutations in the genomic DNA. PCR Methods Appl 1991;1:34-38.
31. Tuck SP, Crawford L: Characterization of the human p53 gene promoter. Mol Cell Biol 1989;9:2163-2172.
32. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning - A Laboratory Manual, ed 2. Cold Spring Harbor, Cold Spring Harbor Press, 1989.
33. Nayak BK, Baral RN, Das BR: p53 gene mutation in relation of p53 protein accumulation in male and female breast cancer. Neoplasma 1996;43:305-309.
34. Grubb GR, Yun K, Reeve AE, Eccles MR: Exclusion of the Wilms tumour gene (WT1) promoter as a site of frequent mutation in Wilms tumour. Oncogene 1995;10:1677-1681.
35. Sakai T, Ohtani N, McGee TL, Robbins PD, Dryja TP: Oncogenic germ-line mutations in Sp1 and ATF sites in the human retinoblastoma gene. Nature 1991;353:83-86.
36. Bookstein R, Rio P, Madreperla SA, Hong F, Allred C, Grizzle WE, Lee W-H: Promoter deletion and loss of retinoblastoma gene expression in human prostate cancer. Proc Natl Acad Sci USA 1990;87:7762-7766.
37. Rogel A, Popliker M, Webb CG, Oren M: p53 cellular tumour antigen: Analysis of mRNA levels in normal adult tissues, embryos and tumours. Mol Cell Biol 1985;5: 2851-2855.
38. Baliant E, Reisman D: Increased rate of transcription contributes to elevated expression of the mutant p53 gene in Burkitt's lymphoma cells. Cancer Res 1996;56:1648-1653.